

# THE LANCET Neurology

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. *Lancet Neurol* 2020; published online Oct 5. [https://doi.org/10.1016/S1474-4422\(20\)30308-2](https://doi.org/10.1016/S1474-4422(20)30308-2).

# Neuropathology of SARS-CoV-2: a post mortem case series

Jakob Matschke<sup>1</sup>, Marc Lütgehetmann<sup>2</sup>, Christian Hagel<sup>1</sup>, Jan P. Sperhake<sup>3</sup>, Ann Sophie Schröder<sup>3</sup>, Caroline Edler<sup>3</sup>, Herbert Mushumba<sup>3</sup>, Antonia Fitzek<sup>3</sup>, Lena Allweiss<sup>4</sup>, Maura Dandri<sup>4,7</sup>, Matthias Dottermusch<sup>1</sup>, Axel Heinemann<sup>3</sup>, Susanne Pfefferle<sup>2</sup>, Marius Schwabenland<sup>9</sup>, Daniel Sumner Magruder<sup>5</sup>, Stefan Bonn<sup>5;8</sup>, Marco Prinz<sup>9</sup>, Christian Gerloff<sup>6</sup>, Klaus Püschel<sup>3</sup>, Susanne Krasemann<sup>1</sup>, Martin Aepfelbacher<sup>2</sup> and Markus Glatzel<sup>1</sup>,

<sup>1</sup>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>2</sup>Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>3</sup>Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>4</sup>I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>5</sup>Institute of Medical Systems Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

<sup>6</sup>Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>7</sup>German Center for Infection Research, Partner Site Hamburg-Borstel-Lübeck-Riems, Germany

<sup>8</sup>German Center for Neurodegenerative Diseases, Tuebingen, Germany.

<sup>9</sup>Institute of Neuropathology, University of Freiburg, Freiburg, Germany

## Supplementary data

### Contents:


**Page 2: Suppl. Fig 1.** Establishment of SARS-CoV-2 staining on paraffin embedded cells

**Page 3: Suppl. Fig 2.** Examples of immunostaining for CD8 in the lower brainstem


**Page 4: Suppl. Fig 3.** Staining of SARS-CoV-2 viral proteins in cranial nerves

**Page 5: Suppl. Table 1:** Histopathological analysis of microgliosis based on Iba1-immunoreactivity.


**Suppl. Fig 1.** Establishment of SARS-CoV-2 staining on paraffin embedded cells  
Vero-cells were either infected with SARS-CoV-2 (Hamburg isolate) or mock infected, fixed in formalin, and embedded into paraffin blocks. Paraffin sections were cut and stained. Representative images of virus protein detection with anti-Spike (S2 subunit) or two different anti-nucleoprotein antibodies show highly specific staining in virus infected cells only. As expected, anti-Spike antibody displayed a subcellular staining pattern that is distinct from those of both nucleoprotein antibodies. Mock infected cells show no or only very weak background staining. Scale bar: 50  $\mu$ m.



**Suppl. Fig 2.** Examples of immunostaining for CD8 in the lower brainstem (a: 1+, b: 2+, c: 3+) and GFAP in the frontal cortex (d: 1+ (slight: occasional reactive astrocytes), e: 2+ (moderate: scattered confluent reactive astrocytes), f: 3+ (severe: numerous reactive astrocytes) in patients with fatal SARS-CoV-2-infection (COVID-19). Scale bar: 100  $\mu$ m



**Suppl. Fig 3.** Staining of SARS-CoV-2 viral proteins in cranial nerves could be detected in two cases of this study. A) Spike protein was detected in one case; Scale bar: 50 $\mu$ m and B) nucleoprotein in another; Scale bar: 100 $\mu$ m. Brain macrophages/microglia as detected by Iba1 did not co-localize with positive signal in consecutive sections. Secondary antibody only control did not show relevant background signal.



**Suppl. Table 1:**

Histopathological analysis of microgliosis based on Iba1-immunoreactivity.

ID	upper medulla
1	severe
2	severe
3	n.d.
4	n.d.
5	severe
6	moderate
7	severe
8	severe
9	technical issues: n.d.
10	technical issues: n.d.
11	moderate / severe
12	severe
13	slight
14	moderate
15	n.d.
16	severe
17	moderate
18	severe
19	moderate
20	severe
21	severe
22	slight
23	none
24	severe
25	severe
26	none
27	severe
28	slight
29	severe
30	moderate
31	severe
32	moderate
33	moderate
34	severe